1. Pink Sheet
  2. >>Market Access

Paying For Obesity Drugs: The Looming Affordability Crisis

 
• By Jessica Merrill

As use of new obesity medicines become more widespread, experts at the J.P. Morgan Healthcare conference predicted that paying for them will stress state governments and employers.

money on a scale
Paying for new obesity drugs will be a costly proposition • Source: Shutterstock

Despite the unbridled enthusiasm for new obesity drugs, which are expected to drive pharmaceutical sector growth along with delivering weight loss and related health benefits to patients, paying for the long-term use of the chronic treatments in widespread patient populations is going to present an affordability crisis, experts said at the J.P. Morgan Healthcare Conference.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.